New Jersey A 3265: Establishes a Personal Care Assistance Task Force in Department of Human Services.

Bill Text

A3265 

ASSEMBLY, No. 3265 

STATE OF NEW JERSEY

222nd LEGISLATURE

� 

PRE-FILED FOR INTRODUCTION IN THE 2026 SESSION

Sponsored by:

Assemblyman DAN HUTCHISON

District 4 (Atlantic, Camden and Gloucester)

SYNOPSIS

���� Establishes certain prescription drug data reporting 
requirements for hospitals.

CURRENT VERSION OF TEXT 

���� Introduced Pending Technical Review by Legislative 
Counsel.

�� 

An Act concerning prescription drug prices and hospitals and 
amending and supplementing P.L.2023, c.106 (C.45:14-82.2 et seq.).

���� Be It 
Enacted by the Senate and General Assembly of 
the State of New Jersey:

���� 1.� Section 1 of P.L.2023, 
c.106 (C.45:14-82.2) is amended to read as follows:

� �� 1.��� As used in P.L.2023, 
c.106 (C.45:14-82.2 et seq.) and P.L. , c. (C. ) 
(pending before the Legislature as this bill):

���� "Biosimilar" means a 
drug that is produced or distributed pursuant to a biologics license 
application approved under 42 U.S.C. s.262(k)(3).

���� "Brand-name drug" 
means a prescription drug approved under 21 USC s.355(b) or 42 USC s.262.

���� "Carrier" means the 
same as that term is defined in section 2 of P.L.1997, c.192 (C.26:2S-2).

���� "Division" means the 
Division of Consumer Affairs in the Department of Law and Public Safety.

���� "Drug group" means a 
group of drugs defined by the division for the purpose of facilitating revenue 
and cost reporting by manufacturers, carriers, pharmacy benefits managers, and 
wholesalers under sections 2 through 6 of P.L.2023, c.106 (C.45:14-82.3 through 
45:14-82.7) and hospitals under section 6 of P.L.��� , c.��� (C.������� ) 
(pending before the Legislature as this bill).

���� "Hospital" means 
a general acute care hospital licensed pursuant to P.L.1971, c.136 (C.26:2H-1 
et seq.).

���� "Logistics provider" 
means an entity that receives a prescription drug product from the original or 
contract manufacturer, warehouses and delivers the prescription drug product at 
the direction of the manufacturer, and does not purchase, sell, trade, or take 
title to the prescription drug product.

���� "Manufacturer" means 
a business registering under P.L.1961, c.52 (C.24:6B-1 et seq.) as a drug 
manufacturing business as defined in section 13 of P.L.1961, c.52 (C.24:6B-12).

���� "Market 
introduction" means the month and year in which a manufacturer acquired or 
first marketed a drug for sale in New Jersey.

���� "Medicare Part D 
specialty threshold" means the specialty tier cost threshold established 
by the Centers for Medicare and Medicaid Services.

���� "New drug" means a 
prescription drug that has received initial approval under an original new drug 
application under 21 U.S.C. s.355(b), under an abbreviated new drug application 
under 21 U.S.C. s.355(j), or under a biologics license application under 42 
U.S.C. s.262.� In cases where multiple products are included on an application, 
each product shall be considered a new prescription drug.

���� "Pharmacy benefits 
manager" means a corporation, business, or other entity, or unit within a 
corporation, business, or other entity that, pursuant to a contract or under an 
employment relationship with a carrier, a self-insurance plan or other third-party 
payer, either directly or through an intermediary, administers prescription 
drug benefits on behalf of a carrier, self-funded plan, or other third-party 
payer.

���� "Pharmacy services 
administrative organization" means an entity operating within the State 
that contracts with independent pharmacies to conduct business on their behalf 
with third-party payers.

���� "Pricing unit" means 
the smallest dispensable amount of a prescription drug that could be dispensed.

���� "Reporting entity" 
means any manufacturer, carrier, pharmacy benefits manager, wholesaler, 
pharmacy services administrative organization, hospital, or any other 
entity required to report to the division under P.L.2023, c.106 (C.45:14-82.2 
et seq.) or P.L. , c. (C. ) 
(pending before the Legislature as this bill).

���� "Wholesale acquisition 
cost (WAC)" means, with respect to a prescription drug, the manufacturer's 
list price for the drug to wholesalers or direct purchasers in New Jersey, as 
defined in 42 U.S.C. s.1395w-3a(c)(6)(B), excluding any discounts, rebates, or 
reductions in price, for the most recent month for which the information is 
available, as reported in wholesale price guides or other publications of 
prescription drug pricing.

���� "Wholesaler" means a 
business registering under P.L.1961, c.52 (C.24:6B-1 et seq.) as a wholesale 
drug business as defined in section 13 of P.L.1961, c.52 (C.24:6B-12).� 
"Wholesaler" shall not include a common carrier, or an employee thereof, 
whose possession of a prescription drug product is in the usual course of the 
common carrier's or employee's business or employment, and shall not include a 
logistics provider or an employee thereof.

(cf: P.L.2023, c.106, s.1)

���� 2.� Section 7 of P.L.2023, 
c.1